ScripSeagen Inc. reached multi-product status in 2020 with the launch of two new cancer drugs – Padcev (enfortumab vedotin) and Tukysa (tucatinib) – and now the company has set its ambitions on further p
ScripSeattle Genetics, Inc. has landed Merck & Co., Inc. . as a partner for two cancer therapies, including an antibody-drug conjugate (ADC), in a wide-spanning collaboration that will provide an influx
ScripSeattle Genetics Inc. appears on track to bring a competitive new drug to market for advanced or metastatic HER2-positive breast cancer late next year in what is an increasingly crowded therapeutic a
ScripSeattle Genetics Inc. plans to rapidly launch Tukysa (tucatinib) following the 17 April US Food and Drug Administration approval of its breast cancer drug – a decision that came four months before th